Progentec诊断公司通过新的研究和OCAST资助提高了确定狼疮风险的能力

New immune index supports earlier identification of patients at risk for lupus before clinical diagnosis, supporting earlier intervention and improved outcomes

新的免疫指标有助于在临床诊断之前更早地识别有患狼疮风险的患者，从而支持更早的干预和改善预后。

OKLAHOMA CITY

俄克拉荷马城

,

，

April 9, 2026

2026年4月9日

/PRNewswire/ -- Progentec Diagnostics, Inc., a leader in precision diagnostics for autoimmune diseases, today announced the publication of new research in

/PRNewswire/ -- 精准诊断自身免疫性疾病领域的领导者Progentec Diagnostics, Inc.今天宣布新的研究成果发表在

Lupus Science & Medicine

狼疮科学与医学

and the award of an Oklahoma Center for the Advancement of Science and Technology (OCAST) Industry Innovation Grant to further develop its lupus classification risk blood test.

并且获得了俄克拉荷马州科学与技术发展中心 (OCAST) 的行业创新奖助金，以进一步开发其狼疮分类风险血液测试。

The peer-reviewed study, led by Dr. Melissa E. Munroe, MD, PhD, Chief Scientific Officer at Progentec and Principal Investigator, and her colleagues at the Oklahoma Medical Research Foundation, introduces a novel immune-based index that has the potential to identify individuals at risk of developing systemic lupus erythematosus (SLE) and characterize disease activity..

这项由 Melissa E. Munroe 医学博士、哲学博士，Progentec 首席科学官兼首席研究员，以及她在俄克拉荷马医学研究基金会的同事领导的经同行评议的研究，引入了一种新的基于免疫的指标，该指标有潜力识别出系统性红斑狼疮 (SLE) 的高风险个体，并描述疾病活动特征。

'For the first time, we are capturing immune pathway dysregulation that occurs in lupus pathogenesis in a single blood test,' said Melissa E. Munroe, MD, PhD.

“我们首次在单次血液检测中捕捉到狼疮发病过程中出现的免疫通路失调，”医学博士、哲学博士梅丽莎·E·门罗说。

Identifying Lupus Risk Before Clinical Classification

识别临床分类前的狼疮风险

Systemic lupus erythematosus is a complex autoimmune disease often diagnosed only after significant organ involvement has occurred. Early identification of at-risk individuals remains a major unmet need in patient care.

系统性红斑狼疮是一种复杂的自身免疫性疾病，通常在重要器官受累后才被诊断出来。早期识别高风险个体仍是患者护理中尚未满足的主要需求。

The study describes the development of a

研究描述了开发过程

Lupus Classification Risk Immune Index (L-CRI)

系统性红斑狼疮分类风险免疫指数 (L-CRI)

, a composite score derived from dysregulated immune mediators and lupus-associated autoantibody specificities. The L-CRI was shown to differentiate and identify at-risk individuals who later developed lupus months to years before clinical disease classification for SLE.

，一个由免疫介质失调和狼疮相关自身抗体特异性得出的综合评分。研究表明，L-CRI 能够区分并识别出在系统性红斑狼疮（SLE）临床分类之前的数月甚至数年内发病的高危个体。

Grant Funding to Accelerate Clinical Translation

资助以加速临床转化

Building on these findings, Progentec has been awarded an Oklahoma Center for the Advancement of Science and Technology (OCAST) Industry Innovation Grant, a competitive state-funded program designed to support technologies with strong potential for commercialization. The grant will support development and clinical validation of Progentec's lupus classification risk test..

基于这些发现，Progentec 获得了俄克拉荷马州科学与技术发展中心 (OCAST) 的行业创新资助，这是一个竞争性的州立资助项目，旨在支持具有强大商业化潜力的技术。该资助将用于支持 Progentec 的狼疮分类风险测试的开发和临床验证。

'This test will further strengthen Progentec's commitment to developing a comprehensive precision diagnostics platform for autoimmune diseases,' said Mohan Purushothaman, CEO of Progentec Diagnostics.

“这项测试将进一步加强Progentec致力于开发一个全面的自身免疫疾病精准诊断平台的承诺，”Progentec诊断公司的首席执行官莫汉·普鲁索塔曼表示。

About Progentec Diagnostics, Inc.

关于Progentec诊断公司

Progentec Diagnostics is dedicated to improving health outcomes for individuals with autoimmune diseases through clinically validated biomarker testing (aiSLE

Progentec诊断公司致力于通过临床验证的生物标志物检测（aiSLE）来改善自身免疫性疾病患者的健康状况。

®

®

DX Flare Risk Index and aiSLE

DX耀斑风险指数和aiSLE

®

®

DX Disease Activity Index for Lupus) and digital health technologies (CareMGMT

系统性红斑狼疮的DX疾病活动指数和数字健康技术（CareMGMT）

™

™

app). Partnering with researchers, healthcare providers, and patient communities, Progentec works to close diagnostic gaps and bring precision medicine to the forefront of autoimmune care.

与研究人员、医疗保健提供者和患者社区合作，Progentec 致力于缩小诊断差距，并将精准医疗带到自身免疫性疾病治疗的前沿。

To learn more about Progentec's lupus testing solutions or how to order, visit

要了解更多关于Progentec的狼疮检测解决方案或如何订购的信息，请访问

www.progentec.com

www.progentec.com

Contact:

联系人：

Heather Iyer

贺ather Iyer

[email protected]

电子邮件地址

SOURCE Progentec Diagnostics, Inc.

来源：Progentec诊断公司

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示